News

Donaldson, with its Univercells Technologies business, announces that the Gene Therapy Program at the University of Pennsylvania (GTP) is expanding its evaluation agreement aimed at determining the scalability of GTP’s gene therapy product manufacturing using Univercells Technologies’ bioreactors.

Donaldson, with its Univercells Technologies business, announces that the Gene Therapy Program at the University of Pennsylvania (GTP) is expanding its evaluation agreement aimed at determining the scalability of GTP’s gene therapy product manufacturing using Univercells Technologies’ bioreactors.

Research Triangle Park, a North Carolina technology and biotech hub, is Donaldson’s choice for the latest expansion of its life sciences footprint.

Donaldson announced its Isolere Bio and Univercells Technologies businesses are developing an integrated upstream and downstream platform for viral vector manufacturing.

Donaldson has announced it acquired Solaris Biotechnology Srl. Solaris designs and manufactures bioprocessing equipment, including bioreactors, fermenters and tangential flow filtration systems for use in food and beverage, biotechnology and other life sciences markets.

Donaldson has announced the acquisition of Purilogics, LLC, an early-stage biotechnology company that leverages a novel technology platform for the development of best-in-class membrane chromatography products.

Donaldson Company Inc. has entered into a definitive agreement allowing the Company to purchase a 49% stake in Medica S.p.A. (Medica)

Donaldson has acquired Isolere Bio, Inc., a biotechnology company that develops reagents and filtration processes for biopharmaceutical purification and manufacturing.

Donaldson today announced the acquisition of Univercells Technologies, a global producer of innovative biomanufacturing solutions for cell and gene therapy research, development and commercial manufacturing.